SHADI DAOUD: Open Payments
NPI 1699739151 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,820 in 79 payments from 20 companies in 2025. Trend: 2023 $1,438 · 2024 $1,837 · 2025 $1,820
Food & beverage: $1,820
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 13 | $314 |
| E.R. Squibb & Sons, L.L.C. | 9 | $189 |
| Amgen Inc. | 13 | $181 |
| Boston Scientific Corporation | 4 | $138 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $132 |
| Novo Nordisk Inc | 6 | $112 |
| BridgeBio Pharma, Inc. | 4 | $111 |
| PFIZER INC. | 5 | $94 |
| Alnylam Pharmaceuticals Inc. | 3 | $88 |
| Abbott Laboratories | 3 | $80 |
Products named: LEQVIO, Repatha, CAMZYOS, WATCHMAN FLX, JARDIANCE, Wegovy, Attruby, VYNDAQEL.
Industry payments across NV — which companies pay providers there.
